Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials

Jiří Beran,Jason D. Lickliter,Tino F. Schwarz,Casey Johnson,Laurence Chu,Joseph B. Domachowske,Pierre Van Damme,Kanchanamala Withanage,Laurence Fissette,Marie-Pierre David,Koen Maleux,Alexander C. Schmidt,Marta Picciolato,Ilse Dieussaert

Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials

2018

Jiří Beran
Jason D. Lickliter
Tino F. Schwarz
Casey Johnson
Laurence Chu
Joseph B. Domachowske
Pierre Van Damme
Kanchanamala Withanage
Laurence Fissette
Marie-Pierre David
Koen Maleux
Alexander C. Schmidt
Marta Picciolato
Ilse Dieussaert

Background Respiratory syncytial virus (RSV) causes bronchiolitis and pneumonia in neonates and infants. RSV vaccination during pregnancy could boost preexisting neutralizing antibody titers, providing passive protection to newborns.

Keywords:

Virology
Virus
Immune system
Immunogenicity
Respiratory Syncytial Virus Vaccines
Immunology
Respiratory system
Diphtheria
Pregnancy
Medicine
Tetanus
Antibody titer
Vaccination
Neutralizing antibody
Bronchiolitis
Reactogenicity

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations